Monthly Archives: June 2015

Biothera Announces Preclinical Research Collaboration with Eli Lilly and Company

EAGAN, MN — June 30, 2015 — Biothera announced today that it has signed a collaborative research agreement with Eli Lilly and Company (NYSE: LLY) to evaluate in preclinical models the combination of Biothera’s investigational immunotherapy Imprime PGG and Lilly’s anti-angiogenic therapy, ramucirumab (Cyramza®). Emerging data illustrate the enormous potential of therapies that activate the immune system to recognize and eradicate cancer cells. In many...

Read More


Biothera CMO to Address the World NSCLC Summit

BOSTON — June 23, 2015 — Biothera Chief Medical Officer Ada Braun, M.D., Ph.D. will deliver a presentation today on harnessing the innate immune system to increase the efficacy of cancer-targeted antibodies in non-small cell lung cancer (NSCLC) at the World NSCLC Summit. Biothera is pioneering the development of innate immune modulation to initiate a coordinated immune response to kill cancer cells. The company’s late...

Read More


Investigator-Sponsored Trial Evaluating Biothera’s Imprime PGG in Relapsed Indolent Non-Hodgkin Lymphoma

EAGAN, MN — June 22, 2015 — Biothera today announced that patient dosing has begun in an investigator-sponsored phase 2 trial of its investigational cancer immunotherapy, Imprime PGG, in combination with rituximab (Rituxan®) for relapsed indolent Non-Hodgkin Lymphoma (NHL). The trial is being conducted at the Dana-Farber Cancer Institute under the direction of Caron A. Jacobson, M.D., Instructor in Medicine, Harvard Medical School. “Rituximab, as...

Read More


Biothera to Participate in Webcast on Advances in Cancer Immunotherapy

EAGAN, MN — June 18, 2015 — Jeremy Graff, Ph.D., Senior Vice President, Pharmaceutical Research for Biothera, will participate in a BioPharma Dealmakers webcast featuring four companies developing cancer immunotherapies. The webcast is scheduled for 11:00 am ET on July 21. Webcast registration. The webcast will explore some of the challenges and opportunities of technologies at the cutting edge of cancer immunotherapy. Participants will learn...

Read More


Dan Conners Steps Down as Biothera Board Chairman and President of its Pharmaceutical Business

CEO Richard Mueller Elected Chairman Steve Smith Named Pharmaceutical President EAGAN, MN — June 5, 2015 — The Board of Directors of Biothera announced today that Dan Conners has stepped down as President of the company’s pharmaceutical business, as Chairman of the Board and as a Board member, effective immediately. The Board also announced that Richard Mueller, Biothera Chief Executive Officer since 2001, has been...

Read More